media – Page 536 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) were published in the peer-reviewed journal The Lancet.
- Source: Novartis
- 536
- March 26, 2018
Clinical Trials SPMS
Big Events on Pharmaceuticals during NPC & CPPCC

The two sessions (NPC & CPPCC) this year have received much attention from China and outside China, wherein, the most-watched theme is “reform”. Regarding pharmaceuticals, the event that attracts the highest attention is CFDA reform, followed by policy moves of the TCM issue and bio-medicine, etc. that China has been strongly supporting in recent years.
- Source: EN-CPhI
- 1,116
- March 26, 2018
CFDA China CPhI pharmaceutical Policies
AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch

AbbVies stock $ABBV is getting hammered this morning after its $10 billion Rova-T program posted poor mid-stage results for third-line small cell lung cancer, forcing the company to scuttle any plans to seek an accelerated approval for the closely-watched drug after talks with skeptical regulators.
- Source: 4-traders
- 608
- March 26, 2018
AbbVies Clinical Trials Company Insights small cell lung cancer
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA Priority Review designation; provides clinicians with pediatric-specific safety and clinical data Novartis continues commitment to people living with CML, including pediatric patients with this cancer
- Source: novartis
- 633
- March 26, 2018
chronic myeloid leukemia Clinical Trials FDA Tasigna®
Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round

SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners.
- Source: BusinessWire
- 444
- March 26, 2018
Company Insights funding medical device products ostomy
Device developed which eliminates risk of air embolism

Medical device design agency, Team Consulting, has created the Convesaid haemostat spray device that stops bleeds during surgery.
- Source: MedicalPlasticsNews
- 513
- March 26, 2018
medical device products Researches surgery
Smiths Medical touts FDA nod, US launch of DeltaVan catheter

Smiths Medical today touted the FDA clearance and US launch of Delta Med’s DeltaVan closed system catheter.
- Source: MassDevice
- 566
- March 26, 2018
catheter FDA medical device products New Approvals
Eli Lilly gets a date with FDA experts for once-rejected rheumatoid arthritis drug baricitinib

Eli Lilly’s one-time blockbuster hopeful baricitinib $LLY is back and on track and ready to run a gamut of outside experts at the FDA.
- Source: Endpts
- 625
- March 23, 2018
baricitinib Company Insight FDA
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125 million.
- Source: tcr2
- 496
- March 23, 2018
blood cancer Market Views solid tumor TCR
Brain ‘Stethoscope’ Listens For Silent Seizures

Researchers have developed what they have dubbed a ‘brain stethoscope’, a device capable of turning EEG brain wave data into sound. The device is able to detect epileptic seizures that do not result in convulsions.
- Source: Neuroscience News
- 1,298
- March 23, 2018
medical device neuroscience Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.